(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/212884 A1

(51) International Patent Classification:
A61K 9/51 (2006.01) *A61P 1/00* (2006.01)
A61K 47/26 (2006.01) *C12N 15/00* (2006.01)

(21) International Application Number:
PCT/US2022/023120

(22) International Filing Date:
01 April 2022 (01.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/169,751 01 April 2021 (01.04.2021) US

(71) Applicant: **CODIAK BIOSCIENCES, INC.** [US/US]; 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(72) Inventors: **O'NEIL, Conlin**; c/o Codiak BioSciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **BOURDEAU, Raymond**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **ELLIS, Kimberly**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **WOOD, Andrew**; c/o Codiak Biosciences, Inc., 35 CambridgePark Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C. 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: EXTRACELLULAR VESICLE COMPOSITIONS

(57) Abstract: The present disclosure relates to compositions comprising extracellular vesicles (*e.g.*, exosomes) that can comprise an antisense oligonucleotide (ASO), wherein the composition has an osmolarity that is lower than 450 mOsm/kg. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat and/or prevent a range of medical disorders.

WO 2022/212884 A1